Commun Stat A10:1043–1069CrossRef 33 Penning-van Beest FJ, Goett

Commun Stat A10:1043–1069CrossRef 33. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28:236–242PubMedCrossRef 34. Penning-van Beest FJ, Erkens JA, Olson M (2008) Loss Selleckchem INK 128 of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511–517PubMedCrossRef 35. Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy

and hip fracture risk in osteoporotic women. Osteoporos Int 19:811–818PubMedCrossRef 36. Landfeldt E, Borgstrom F, Robbins S et al (2010) Adherence to treatment of osteoporosis in Sweden: the Swedish Adherence Register Analysis (SARA). Osteoporos Int 21(Suppl1):S252 37. Van den Boogaard CHA, Breekveldt-Postma NS, Borggreve SE et al (2006) Persistent bisphosphonate

use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 22:1757–1764PubMedCrossRef 38. McCoombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287CrossRef 39. EMEA recommends changes in the product information for protelos/osseor due to the risk of severe hypersensitivity reactions (2007). http://​www.​ema.​europa.​eu/​humandocs/​PDFs/​EPAR/​protelos/​PressRelease_​Protelos_​41745807en.​pdf.​ selleck chemical 40. Cooper A, Drake J, Brankin E et al (2006) Treatment persistence with once-monthly

ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896–905PubMedCrossRef 41. ZD1839 manufacturer Weiss TW, Henderson SC, McHorney CA, Cramer JA (2007) Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 23:2193–2203PubMedCrossRef 42. Geusens PP, Lems WF, Verhaar HJ, Leusink G, Goemaere S, Zmierczack H, Compston J (2006) Review and evaluation of the Dutch guidelines for osteoporosis. J Eval Clin Pract 12:539–548PubMedCrossRef 43. McDonald HP, Garg AX, Haynes RB (2002) Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288:2868–2879PubMedCrossRef 44. Gleeson T, Iversen MD, Avorn J et al (2009) Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 20:2127–2134PubMedCrossRef 45. Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRef 46. Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD et al (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296–1304PubMedCrossRef 47.

Comments are closed.